GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Mankind Pharma Ltd

Mankind Pharma Board Approves Amalgamation of Wholly Owned Subsidiaries

M&A ● No Immediate Change LOW RISK
📅 Filed on BSE: 26 Oct 2026, 03:24 PM IST  ·  BSE ID: 62d834b5-a91a-4367-bb09-df2576a89d7e
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board approved financial results and plans to merge two of its fully-owned smaller companies into the main business.
🤖 AI Summary
  • Mankind Pharma Board approved unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026.
  • Scheme of Arrangement approved for amalgamation of wholly-owned subsidiaries Prolijune Lifesciences Private Limited and Pavi Buildwell Private Limited with Mankind Pharma Limited.
  • The appointed date for Scheme 1, involving Prolijune and Pavi Buildwell, is April 01, 2027.
  • Board noted the scheme for amalgamation of Upakarma Ayurveda Private Limited with Mankind Consumer Products Private Limited, a step-down subsidiary.
  • Both amalgamation schemes are subject to necessary statutory and regulatory approvals, including from the NCLT.
🏢 How This Affects the Company
📈
Business Impact
The amalgamation of wholly-owned subsidiaries simplifies the corporate structure by integrating operations of Prolijune Lifesciences and Pavi Buildwell directly into Mankind Pharma.
💰
Financial Impact
Consolidation of wholly-owned subsidiaries removes inter-company transactions and streamlines financial reporting, potentially impacting overall balance sheet presentation post-amalgamation.
⚙️
Operational Impact
Consolidating wholly-owned subsidiaries can streamline operational processes, integrate resources, and eliminate duplicate functions across the merged entities.
⚠️
Risk Impact
The amalgamation is subject to various statutory and regulatory approvals, including NCLT, introducing procedural risks until final approval and implementation.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders as the amalgamation process is ongoing and subject to approvals.
👤
Who Is Affected
Shareholders of Mankind Pharma Limited are indirectly affected by the corporate restructuring, which aims to simplify the overall entity, contingent on future approvals.
🔍
Management Signal
The decision signals management's intent to simplify the corporate structure and consolidate wholly-owned and step-down subsidiaries for potential operational efficiencies.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
NCLT approval for Scheme 1 (Prolijune and Pavi Buildwell) and Scheme 2 (Upakarma Ayurveda).
Effective date of amalgamation for both schemes post-regulatory clearances.
Company disclosures regarding the outcome of statutory and regulatory approvals.
LOW RISK The amalgamation involves wholly-owned subsidiaries, reducing direct risks to external shareholders, but is subject to regulatory approval.
💡 Investor Takeaway
Mankind Pharma's Board approved the amalgamation of two wholly-owned subsidiaries, Prolijune Lifesciences and Pavi Buildwell, with an appointed date of April 01, 2027. The scheme, along with another for a step-down subsidiary, aims to streamline the corporate structure but awaits statutory and regulatory approvals.
⚖️ Strengths & Concerns

✅ Positives

  • Amalgamation of wholly-owned subsidiaries simplifies the corporate structure and consolidates administrative processes.
  • The scheme streamlines legal and regulatory compliance by reducing the number of separate entities to manage.

⚠️ Concerns

  • The amalgamation schemes require various statutory and regulatory approvals, including NCLT, which could delay final implementation.
  • The appointed date for Scheme 1 is April 01, 2027, indicating a time lag until the full integration and benefits materialize.
📅 Company Track Record
Mankind Pharma has been active in acquisitions, having acquired a 70% stake in ACTx for EUR 48Mn in October 2026, fully acquired Upakarma Ayurveda for ₹75 Lakhs in June 2026, and acquired the Rivotril CNS brand from Roche in March 2026.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What did Mankind Pharma's Board approve in its meeting on October 26, 2026?
The Board approved the unaudited Standalone and Consolidated Financial Results for Q2/H1 FY2027 and schemes of amalgamation involving its wholly-owned subsidiaries.
Which wholly-owned subsidiaries are being amalgamated with Mankind Pharma Limited?
Prolijune Lifesciences Private Limited and Pavi Buildwell Private Limited are being amalgamated with Mankind Pharma Limited.
What is the appointed date for the amalgamation of Prolijune Lifesciences and Pavi Buildwell?
The appointed date for the amalgamation of Prolijune Lifesciences Private Limited and Pavi Buildwell Private Limited is April 01, 2027.
Is the amalgamation of Upakarma Ayurveda Private Limited also approved by Mankind Pharma's Board?
Mankind Pharma's Board considered and took note of the scheme of amalgamation of Upakarma Ayurveda Private Limited with Mankind Consumer Products Private Limited, a step-down wholly-owned subsidiary.
Are these amalgamation schemes final?
No, both amalgamation schemes are subject to necessary statutory and regulatory approvals, including from the Hon’ble National Company Law Tribunal (NCLT).

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.